Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vebreltinib Neoadjuvant in MET-altered NSCLC
NCT06644313Phase 2Not yet recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Nov 2024
- Primary completion
- Nov 2029
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of vebreltinib in non-small cell lung cancer (NSCLC), sponsored by Shanghai Pulmonary Hospital. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
vebreltinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06644313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06644313.